68,181 Shares in Evolus, Inc. (NASDAQ:EOLS) Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 68,181 shares of the company’s stock, valued at approximately $753,000. Jefferies Financial Group Inc. owned 0.11% of Evolus at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Nantahala Capital Management LLC grew its holdings in Evolus by 10.8% during the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock worth $34,557,000 after acquiring an additional 305,300 shares during the period. Caligan Partners LP grew its holdings in Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after acquiring an additional 498,900 shares during the period. Boothbay Fund Management LLC grew its holdings in Evolus by 30.9% during the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock worth $14,217,000 after acquiring an additional 304,065 shares during the period. Geode Capital Management LLC grew its holdings in Evolus by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock worth $13,412,000 after acquiring an additional 3,969 shares during the period. Finally, Soros Fund Management LLC grew its holdings in Evolus by 29.4% during the fourth quarter. Soros Fund Management LLC now owns 1,100,000 shares of the company’s stock worth $12,144,000 after acquiring an additional 250,000 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Insider Activity at Evolus

In related news, insider Rui Avelar sold 27,904 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the sale, the insider now owns 362,467 shares of the company’s stock, valued at $4,806,312.42. This trade represents a 7.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Moatazedi sold 15,787 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $155,817.69. Following the sale, the insider now directly owns 492,832 shares in the company, valued at approximately $4,864,251.84. The trade was a 3.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 86,241 shares of company stock valued at $1,048,666 over the last quarter. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on EOLS shares. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a report on Thursday, May 8th. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, BTIG Research assumed coverage on Evolus in a report on Thursday, April 17th. They issued a “buy” rating and a $21.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $23.75.

Evolus Stock Up 0.1%

Evolus stock opened at $10.00 on Friday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm has a market capitalization of $644.76 million, a price-to-earnings ratio of -10.99 and a beta of 1.11. Evolus, Inc. has a fifty-two week low of $8.67 and a fifty-two week high of $17.82. The stock’s fifty day moving average is $11.38 and its two-hundred day moving average is $12.41.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.